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Editorial
The world is suffering from an obesity epidemic 
and most healthcare systems are under tremen-
dous strain to deal with these patients. With 
obesity comes cardiovascular disease, Type II 
diabetes, increased cancer incidences and 
ultimately reduced life expectancy (FigurE 1) [1,2]. 
Up until now, drug therapy has failed in 
making a major impact in the treatment of 
obesity. The most recent drug advances such as 
Rimonabant™ and Sibutramine™ have failed. 
A surgical approach is another option. Gastric 
banding, however, is expensive and approximately 
only 1% of eligible patients have the surgery. 
Would this be tolerated if it was hip replacement 
patients? Treating larger numbers of patients 
for obesity will require drugs that have fewer 
side effects with better than 10% weight loss at 
reasonable cost.
Adipose tissue was originally thought to be 
only for storage of triglycerides and nothing 
else, but advances over the last 15 years have 
shown that white adipose tissue (WAT) is a 
major endocrine organ producing clearly inden-
tified adipokines (leptin and adiponectin) and 
cytokines (TNF-a and IL-6). There is also 
migration of macrophages and therefore chronic 
inflammation (FigurE2) [3].
Understanding these new adipokines and 
their place in metabolic disease will hope-
fully lead to new targets and therapies for the 
treatment of metabolic disease. 
Adipokines as possible targets 
for therapy
  Leptin
Leptin is a 16-kDa nonglycosylated peptide 
belonging to the cytokine class 1 super family. 
It was identified as the first adipokine as it is 
almost exclusively expressed in WAT, particu-
larly in subcutaneous fat (where 80% of leptin 
is produced) [4].
Originally thought only to act centrally, it is 
now clear that it acts peripherally in a large num-
ber of tissues, for example adipocytes where it 
can influence the rate of lipolysis. It also reduces 
food intake and increases energy consumption, 
as well as inhibiting orexigenic neuropeptides [5]. 
Although this protein was not successful when 
put into clinical practice, it has opened up a field 
of research that should provide a more targeted 
approach to obesity treatment.
  Adiponectin 
Adiponectin is a protein produced mainly in 
WAT that increases fatty acid oxidation while 
reducing glucose synthesis in the liver [6]. In 
knock-out mice on a normal diet there is no 
effect but on a high-fat diet mice develop severe 
insulin resistance and have lipid accumulation in 
muscles. These findings suggest that adiponectin 
has a key role to play in energy balance [7].
There is decreased adiponectin expression 
observed in obese patients and this is associ-
ated with insulin resistance and Type II dia-
betes. Adiponectin can affect hepatic glucose 
and decrease mRNA for key gluconeogenisis 
enzymes [8]. This indicates that it may be a use-
ful target in metabolic disease, especially now 
two key receptors, adipoR1 and adipoR2 have 
been shown to play a role in lipid and glucose 
metabolism, inflammation and oxidative stress. 
These appear to warrant further investigation.
  Resistin
In the search for new and improved thiazolidin-
ediones (TZDs), resistin was identified. Resistin 
is increased in obese animals and decreased in 
the presence of TZDs; it is also able to decrease 
glucose transport in vitro [9]. It has the abil-
ity to inhibit adipocyte differentiation [10] and 
therefore may be a good target for the treate-
ment of  Type II diabetes. In humans there have 
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been contradictory results. First, there is debate 
about which organ secretes resistin. Second, 
there is also debate about the circulating levels 
in plasma. Further studies are required to eluci-
date its mechanism of action, however it would 
appear to be a potential target for therapy.
  Zinc-a2-glycoprotein 
Zinc-a2-glycoprotein (ZAG) was identified as 
playing a role in lipid metabolism and is thought 
to be responsible for loss of adipose in cancer 
cachexia patients [11]. ZAG stimulates lipolysis 
in murine adipocytes by activation of adenylyl 
cyclase in a GTP-dependent process [12]. ZAG 
has been shown to be produced in the liver, 
brown adipose and WAT [12].
Our group has published a number of papers 
showing reduced weight in normal mice and 
ob/ob mice when dosed with purified ZAG 
with improved glucose tolerance [13,14]. These 
treated mice showed increased energy expendi-
ture though increased uncoupling proteins and 
changes in glucose and fatty acid oxidation. 
Moreover, in both cachectic mice [12] and 
humans [15], expression of ZAG mRNA in 
WAT was found to be increased tenfold [12] and 
2.7-fold [15], respectively. In cachectic cancer 
patients ZAG mRNA showed a negative corre-
lation with body mass index (BMI), but a positive 
correlation with weight loss and serum-glycerol 
levels [15]. In contrast, ZAG mRNA levels in 
WAT have been shown to be downregulated in 
obesity and correlated negatively with fat mass, 
BMI, plasma insulin and leptin [16]. Treatment of 
ob/ob mice with ZAG decreased body weight and 
fat mass and improved the parameters of insulin 
resistance including decreasing plasma levels of 
glucose, insulin and non-esterified fatty acids, 
improving insulin sensitivity and increasing mus-
cle mass [14]. While ZAG overexpression in mice 
reduced both the body weight and weight of epi-
didymal fat [17], ZAG-knockout animals showed 
an increased body weight, especially when fed a 
high-fat diet [18]. These results suggest that ZAG, 
like leptin, is closely associated with fat mass. 
However, while leptin is positively correlated 
with fat mass, ZAG is negatively correlated.
  The endocannabinoid system
Endocannabinoids, although not a true adi-
pokine, can influence lipolysis and fatty acid 
metabolism along with energy balance. Acting 
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Figure 1. Obesity leads to enormous strain on a great deal of the body’s systems leading 
to cardiovascular disease, diabetes and decreased life expectancy.
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though the cannaboid receptor (CB1) they can 
induce glucose uptake and inhibitors can act 
centrally to suppress appetite [19] 
CB1 antagonists (e.g., R imonabant) 
decreases body weight and food intake but 
suppression of other CNS processes leads to 
suicidal thoughts and depression [20]. Perhaps 
a more targeted approach is required that 
avoids the CB1 antagonist crossing over the 
blood–brain barrier, or possibly targeting the 
CB2 receptor.
  Macrophages & inflammation
Macrophage inf iltration into adipose tis-
sue leads to low-grade chronic inflammation 
though the production of adipokines, cyto-
kines (TNF-a and IL-6). BMI correlates 
strongly with the number of macrophages [21], 
which are shown to decrease after gastric 
banding [22].
Pro-inflammatory cytokines in adipose tis-
sue may be due to the presence of these mac-
rophages. Also receptors involved in immune 
response trigger transduction pathways leading 
to increased expression of pro-inflammatory 
cytokines, thus decreasing IRS and inhibiting 
NFkB [23].
Research on adipose tissue and adipokines has 
changed our understanding of the pathophysiol-
ogy of obesity and insulin resistance. Macrophage 
infiltration offers a new target for therapy and 
shows the need to focus on subcellular structures 
and intracellular signaling methods.
Future perspective
Metabolic syndrome, be it insulin resistance, 
obesity, Type II diabetes or a combination 
thereof, is a complex medical target that may 
require a multi-disciplinary approach for 
effective treatment. 
Adipokines offer new targets for therapy. 
I have only touched on a few key adipokines 
here and there are more still to be discovered. 
Ultimately it may mean that a combination of 
drugs is required to effect a change in energy 
balance for successful weight loss and a 
normalization of metabolic balance.
Meanwhile, lifestyle changes, cognitive psy-
chotherapy and government intervention may 
also play a role as health services collapse under 
the pressure of the obesity epidemic. It is direct 
intervention through drugs and surgery that will 
ultimately provide the answers.
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